title: Fluorouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture.
abstract: A subset of leukemic cells is assumed to maintain long-term growth of acute myeloid leukemia (AML) in vivo. Characterization of these AML progenitor cells may further define growth properties of human leukemia. In vitro incubations with 5-fluorouracil (5-FU) have been used for enrichment of normal primitive hematopoietic stem cells. By analogy to normal hematopoiesis, it was hypothesized that primitive leukemic stem cells might be kinetically more inactive than colony-forming cells (colony-forming units-AML [CFU-AML]). To examine this hypothesis, conditions were established for incubation with 5-FU that eliminated all CFU-AML. These conditions selected a 5-FU-resistant AML fraction that was evaluated for its capacity for long-term growth by transplantation into mice with severe combined immunodeficiency (SCID) and long-term culture in the quantitative cobblestone area-forming cell (CAFC) assay. Transplantation of the 5-FU-resistant fraction of four cases of AML into SCID mice resulted in growth of AML. Whereas no CFU-AML survived, 31% to 82% of primitive (week-6) CAFC were recovered from the 5-FU-treated cells. Hematopoietic cells proliferating in the CAFC assay were shown to be leukemic by cytologic, cytogenetic, or molecular analysis. The reduction of AML growth as determined by outgrowth of AML in SCID mice was in the same order of magnitude as the primitive (week-6) CAFC reduction. This indicates that both assays measure closely related cell populations and that the CAFC assay can be used to study long-term growth of AML. These results show a hierarchy of AML cells that includes 5-FU-resistant progenitors. These cells are characterized as primitive (week-6) CAFC and as leukemia-initiating cells in SCID mice.
authors.affiliation: Institute of Hematology, Erasmus University, Rotterdam, The Netherlands.
authors.forename: W
authors.initials: W
authors.lastname: Terpstra
authors.forename: R E
authors.initials: RE
authors.lastname: Ploemacher
authors.forename: A
authors.initials: A
authors.lastname: Prins
authors.forename: K
authors.initials: K
authors.lastname: van Lom
authors.forename: K
authors.initials: K
authors.lastname: Pouwels
authors.forename: A W
authors.initials: AW
authors.lastname: Wognum
authors.forename: G
authors.initials: G
authors.lastname: Wagemaker
authors.forename: B
authors.initials: B
authors.lastname: Löwenberg
authors.forename: J J
authors.initials: JJ
authors.lastname: Wielenga
mesh_terms: D000208:Acute Disease; D000818:Animals; D001483:Base Sequence; D002898:Chromosomes, Human, Pair 8; D017931:DNA Primers / Q000737:chemistry; D005472:Fluorouracil / Q000494:pharmacology*; D016179:Granulocyte Colony-Stimulating Factor / Q000235:genetics; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000473:pathology*; D051379:Mice; D016513:Mice, SCID; D008969:Molecular Sequence Data; D009368:Neoplasm Transplantation; D014411:Neoplastic Stem Cells / Q000187:drug effects*; D017354:Point Mutation; D013997:Time Factors; D014314:Trisomy; D014407:Tumor Cells, Cultured
chemical_list: D017931:DNA Primers; D016179:Granulocyte Colony-Stimulating Factor; D005472:Fluorouracil